Shares of N4 Pharma Plc (LON:N4P – Get Free Report) traded up 5.9% during trading on Wednesday . The company traded as high as GBX 0.45 ($0.01) and last traded at GBX 0.45 ($0.01). 506,331 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 2,216,324 shares. The stock had previously closed at GBX 0.43 ($0.01).
N4 Pharma Trading Up 5.9 %
The business’s 50-day simple moving average is GBX 0.56 and its two-hundred day simple moving average is GBX 0.60. The company has a market capitalization of £1.94 million, a PE ratio of -1.30 and a beta of -0.37.
N4 Pharma Company Profile
RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.
N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.
N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.
Further Reading
- Five stocks we like better than N4 Pharma
- How Can Investors Benefit From After-Hours Trading
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- P/E Ratio Calculation: How to Assess Stocks
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- What is the Nikkei 225 index?
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
